Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of "Hold" from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) have been given a consensus recommendation of "Hold" by the eleven analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $5.06.

A number of research firms have issued reports on DH. Barclays cut their price target on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group reduced their target price on shares of Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a research note on Thursday, January 16th.

Hedge Funds Weigh In On Definitive Healthcare

Several large investors have recently made changes to their positions in DH. Price T Rowe Associates Inc. MD grew its position in shares of Definitive Healthcare by 20.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock valued at $85,000 after purchasing an additional 3,496 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Definitive Healthcare by 9.7% during the 4th quarter. Principal Financial Group Inc. now owns 43,960 shares of the company's stock valued at $181,000 after buying an additional 3,874 shares in the last quarter. Rhumbline Advisers increased its stake in Definitive Healthcare by 5.2% in the 4th quarter. Rhumbline Advisers now owns 81,316 shares of the company's stock worth $334,000 after acquiring an additional 4,034 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Definitive Healthcare by 18.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company's stock worth $120,000 after acquiring an additional 4,500 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Definitive Healthcare by 6.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company's stock valued at $334,000 after acquiring an additional 4,748 shares during the last quarter. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Definitive Healthcare Stock Performance

Shares of DH stock traded up $0.10 during trading hours on Friday, reaching $2.82. The company had a trading volume of 57,087 shares, compared to its average volume of 966,441. The firm has a market cap of $304.46 million, a PE ratio of -0.91, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The business has a fifty day moving average price of $2.69 and a 200-day moving average price of $3.89. Definitive Healthcare has a one year low of $2.15 and a one year high of $6.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). The company had revenue of $62.29 million during the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. Sell-side analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.